Enbrel TNFr:Fc tumor necrosis factor receptor fused to the Fc portion of IgG1 data

IMNX announced positive preliminary results from its pivotal Phase III trial (see BioCentury Extra

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE